S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
NYSE:NVTA

Invitae Stock Forecast, Price & News

$42.01
-1.71 (-3.91 %)
(As of 03/2/2021 05:26 PM ET)
Add
Compare
Today's Range
$41.87
Now: $42.01
$44.48
50-Day Range
$39.80
MA: $49.80
$56.93
52-Week Range
$7.41
Now: $42.01
$61.59
Volume3.11 million shs
Average Volume4.25 million shs
Market Capitalization$7.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy; and a project with Bristol Myers Squibb, Janssen Research & Development, LLC, Novartis, and Genentech to develop a panel for molecular residual disease detection in patients with acute myeloid leukemia to support clinical trial testing across various drug development programs. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Invitae logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone415-374-7782
Employees1,900
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$216.82 million
Book Value$3.93 per share

Profitability

Net Income$-241,960,000.00
Net Margins-183.50%

Miscellaneous

Market Cap$7.42 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.20 out of 5 stars

Medical Sector

825th out of 1,968 stocks

Medical Laboratories Industry

14th out of 39 stocks

Analyst Opinion: 1.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$42.01
-1.71 (-3.91 %)
(As of 03/2/2021 05:26 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Invitae stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View analyst ratings for Invitae
or view top-rated stocks.

What stocks does MarketBeat like better than Invitae?

Wall Street analysts have given Invitae a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Invitae wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Invitae
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) posted its earnings results on Tuesday, February, 16th. The medical research company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.08. The medical research company had revenue of $100.43 million for the quarter, compared to analysts' expectations of $97.87 million. Invitae had a negative net margin of 183.50% and a negative trailing twelve-month return on equity of 81.19%.
View Invitae's earnings history
.

How has Invitae's stock been impacted by COVID-19 (Coronavirus)?

Invitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVTA stock has increased by 164.9% and is now trading at $41.99.
View which stocks have been most impacted by COVID-19
.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $450 million, compared to the consensus revenue estimate of $488.37 million.

What price target have analysts set for NVTA?

7 Wall Street analysts have issued 12 month price objectives for Invitae's shares. Their forecasts range from $20.00 to $65.00. On average, they expect Invitae's stock price to reach $45.14 in the next year. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for Invitae
or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?

Invitae's management team includes the following people:
  • Dr. Sean Emerson George, Co-Founder, Pres, CEO & Chairman (Age 47, Pay $666.79k)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 61, Pay $566.77k)
  • Dr. Robert L. Nussbaum, Chief Medical Officer (Age 71, Pay $500.09k)
  • Mr. Lee Bendekgey, Chief Policy Officer (Age 63, Pay $566.77k)
  • Ms. Katherine A. Stueland, Chief Commercial Officer (Age 45, Pay $545.13k)
  • Mr. Alex Furman, Co-Founder, Culture Tsar & Head of People Analytics
  • Ms. Michele Cargill Ph.D., Co-Founder, Key Projects & Advisor to the CEO
  • Mr. Kenneth D. Knight, Chief Operating Officer (Age 61)
  • Mr. Robert F. Werner, Chief Accounting Officer (Age 48)
  • Mr. Layton Wedgeworth, Chief Technology Officer

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Who are some of Invitae's key competitors?

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.37%), Nikko Asset Management Americas Inc. (6.37%), Clearbridge Investments LLC (1.20%), Price T Rowe Associates Inc. MD (1.20%), Northern Trust Corp (0.86%) and Norges Bank (0.82%). Company insiders that own Invitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae
.

Which major investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Bank of New York Mellon Corp, Wells Fargo & Company MN, State of Michigan Retirement System, Fagan Associates Inc., State of Wisconsin Investment Board, Nikko Asset Management Americas Inc., and Teton Advisors Inc.. Company insiders that have sold Invitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae
or view top insider-selling stocks.

Which major investors are buying Invitae stock?

NVTA stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, Thornburg Investment Management Inc., Charles Schwab Investment Management Inc., Squarepoint Ops LLC, Longitude Cayman Ltd., and Graham Capital Management L.P..
View insider buying and selling activity for Invitae
or or view top insider-buying stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $41.99.

How much money does Invitae make?

Invitae has a market capitalization of $7.42 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 1,900 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

Where are Invitae's headquarters?

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.